Mutual Funds
Mutual Funds
Fund Profile
Scheme Profile
Daily NAV
Historical NAV
Category Returns
Dividend Details
Fund Ranking
MF Activities
All Holdings
What's In / What's Out
MF Trends
MF Tools
  Home   >   MUTUAL FUND  >  MUTUAL FUNDS  >  CATEGORY RETURNS
CATEGORY RETURNS      
AMC : Category : Scheme :
Nippon India Nifty Pharma ETF
TypeInvestment In% of NAVNo. of sharesValue (Rs cr)
Domestic EquitiesSun Pharmaceutical Industries Limited22.53221689972305.5976
Domestic EquitiesDivi's Laboratories Limited9.7278202900131.9357
Domestic EquitiesDr. Reddy's Laboratories Limited9.4862972549128.6585
Domestic EquitiesCipla Limited8.6720898106117.6160
Domestic EquitiesLupin Limited6.581838724089.2666
Domestic EquitiesTorrent Pharmaceuticals Limited5.151216693769.8648
Domestic EquitiesLaurus Labs Limited5.041262103068.3723
Domestic EquitiesAurobindo Pharma Limited4.571444620462.0000
Domestic EquitiesGlenmark Pharmaceuticals Limited4.265224040357.8482
Domestic EquitiesAlkem Laboratories Limited3.71499330550.3847
Domestic EquitiesBiocon Limited3.0212113933540.9762
Domestic EquitiesMankind Pharma Limited2.992418064040.5844
Domestic EquitiesZydus Lifesciences Limited2.626339936635.6195
Domestic EquitiesIPCA Laboratories Limited2.501422160433.9254
Domestic EquitiesJB Chemicals & Pharmaceuticals Limited1.969613072626.7126
Domestic EquitiesGland Pharma Limited1.640612709322.2514
Domestic EquitiesAbbott India Limited1.5537828521.0729
Domestic EquitiesAjanta Pharma Limited1.40016727318.9891
Domestic EquitiesWockhardt Limited1.355613173818.3854
Domestic EquitiesPiramal Pharma Limited1.180698917416.0118
Total 99.9855 1356.0731
Cash & Cash Equivalents and Net AssetsTriparty Repo0.0585 0.7937
Cash & Cash Equivalents and Net AssetsCash Margin - CCIL0.0006 0.0075
Cash & Cash Equivalents and Net AssetsNet Current Assets-0.0446 -0.6050
Total 0.0145 0.1962
 
Back Back TopTop
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.